Navigation Links
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results
Date:3/10/2010

an>.

2009 and Recent Corporate Highlights

On March 8, 2010, the Company's strategic partner Auxilium Pharmaceuticals, Inc. ("Auxilium") announced that XIAFLEX™ was available by prescription in the United States for the treatment of adult Dupuytren's contracture patients with a palpable cord.  

On February 17, 2010, Auxilium announced the list price to distributors of XIAFLEX as $3,250 per vial and stated that it anticipates that Dupuytren's contracture patients treated with XIAFLEX will have 1.5 cords treated, on average, and that each cord will be treated with an average of 1.1 vials of XIAFLEX.

On February 2, 2010, Auxilium received marketing approval from the U.S. Food and Drug Administration (FDA) for XIAFLEX for treatment of Dupuytren's contracture in adult patients with a palpable cord. As a result, BioSpecifics will receive a $1.0 million milestone payment from Auxilium.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
2. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
3. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
4. BioSpecifics Technologies Corp. Announces FDA Approval of XIAFLEX(TM) for Treatment of Dupuytrens Contracture
5. BioSpecifics Technologies Corp. to Present at the Piper Jaffray 21st Annual Health Care Conference
6. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
7. BioSpecifics Technologies Corp. to Present at Cowen and Company 30th Annual Health Care Conference
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2009 Financial Results on March 10, 2010
9. BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytrens Contracture
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... BOSTON , May 22, 2015  In a ... in the U.S., T1D Exchange researchers conclude ... in type 1 diabetes across all age groups, but ... the most up-to-date picture of diabetes treatment, underscoring the ... therapies and technologies that can help type 1 patients ...
(Date:5/21/2015)... CHICAGO , May 21, 2015 /PRNewswire-USNewswire/ ... lump along the side of his neck, ... and took a couple weeks off from ... didn,t go away.                               ... Rendino, 26, was referred to Michel ...
(Date:5/21/2015)... CITY, Calif. , May 21, 2015  Cardica, Inc. ... 2015, new employee Greg Watson , the company,s vice ... shares of the company,s common stock, at a per share ... 20, 2015. The stock option was granted pursuant to Cardica, ... of directors in May 2015 under Rule 5653(c)(4) of the ...
Breaking Medicine Technology:Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4Cardica Announces New Employment Inducement Grant 2
... a clinical study of adults, VYVANSE taken once-daily ... PHILADELPHIA, Oct. 7 Shire plc (LSE: ... that a study published in the September issue ... significantly improved,Attention Deficit Hyperactivity Disorder (ADHD) symptoms in ...
... - Data Presented Today at ACG Annual Scientific ... Ironwood,Pharmaceuticals, Inc. (formerly Microbia, Inc.) and Forest Laboratories,Inc. ... of results from a Phase,2b study assessing linaclotide,s ... syndrome with constipation (IBS-C). Analysis of the data,indicates ...
Cached Medicine Technology:Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5
(Date:5/22/2015)... Carnegie Science Center and ... partnership to develop BodyTech, a dynamic, three-pronged health and ... a new exhibit at the Science Center called BodyWorks, ... new traveling science show, Anatomy Adventure, which will hit ... Designed to explore a wide range of topics surrounding ...
(Date:5/22/2015)... May 22, 2015 Power Systems is proud ... the 2015 race season. Drobeck is in his second year ... a firefighter with the Missoula Fire Department in Missoula, MT. ... Pro in 2014. During his career, he has had 15 ... Drobeck recorded top 10 finishes in all seven of his ...
(Date:5/22/2015)... May 22, 2015 The ... Dental announces that they are now offering complimentary ... other dental treatments. At consultations, patients can discuss ... regarding what certain treatments can achieve and whether ... during this initial appointment. If treatments are chosen, ...
(Date:5/22/2015)... A Phase 3 French study, which ... Clinical Oncology (ASCO)’s annual meeting at the end ... patients who received bevacizumab in addition to the ... Genentech, Inc.) is an antibody that blocks angiogenesis ... used to treat many other cancers, including lung ...
(Date:5/22/2015)... 22, 2015 In an effort to ... Sons is offering to donate $5 dollars for every ... unit or water softening system. Customers have their needs ... Sons gets business; and the Special Olympics receives money. ... Olympics helps over 4.4 million athletes, and boasts a ...
Breaking Medicine News(10 mins):Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2Health News:Parker and Sons is Proud to Support the Special Olympics with Their Everybody Wins Program 2
... the aim to combat AIDS will exploit the unused power ... to aid research and identify drugs used to combat the ... called FightAIDS@Home, aims to enlist about 100,000 computer users to ... when they would otherwise be idle., ,This ...
... to protect Americans from bird flu and other diseases, ... and shipping firms to hand over// passenger and crew ... illnesses., ,The Atlanta-based Centers for Disease Control and ... responding to health threats, has proposed the regulatory overhaul. ...
... duration of breast-feeding is associated with reduction in risk ... Previous studies have already provided evidence for improved insulin ... to their counterparts. ,The study is the first ... between lactation and Type 2 diabetes. More than 1,57,003 ...
... Conservative groups in the United States, who had voiced ... "morning-after" pill, are now having no such qualms about ... manufactured by Merck & Co. and GlaxoSmithKline are still ... the market, but concerns had been voiced about them ...
... Rs 300 million to Christian Medical College (CMC), Vellore, to ... see if stem cells can be developed into heart muscles, ... specialized cells. , ,"It is a matter of great ... project. It will have far-reaching implications in the lives of ...
... Mayo Clinic, in Olmsted County, Minnesota, suggest that Parkinson's ... manual workers,// meaning that an individual's educational and career ... ,The researchers said that probably early Parkinson's triggered a ... than long periods of education increasing susceptibility to the ...
Cached Medicine News:Health News:U.S. To Tighten Sick Passenger, Quarantine Rules 2Health News:Breastfeeding To Reduce Risk Of Type 2 Diabetes 2Health News:Religious groups overcome objections to cervical cancer vaccines 2
The DSL-05-01-MEM Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Measles virus in human serum. This assay is intended fo...
... The Diagnostic Automation, Inc.. (DAI) Measles IgG ... the detection and quantitative determination of IgG ... sera. Individual serum specimens may be ... Paired sera, acute and convalescent, may be ...
The DSL-05-10-MEG Measles IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgG-class antibodies to Measles Virus in human serum. This assay is intended fo...
... The Vitros Cortisol Range Verifiers have ... System with,the Vitros Immunodiagnostic Products Cortisol Reagent ... range verifiers contain low and,high cortisol concentrations, ... range, and can be used,to verify measurement ...
Medicine Products: